病毒学报

[1] Machado V B, Marostica de Sa J, Miranda Prado A K,Alves de Toledo K, Regasini L O, Pereira de Souza F,Caruso I P, Fossey M A. Biophysical and flavonoidbinding studies of the G protein ectodomain of group A human respiratory syncytial virus[J/OL]. Heliyon,2019, 5(3):e01394. DOI:10.1016/j. heliyon. 2019.e01394.

[2] Shan J, Qian W, Shen C, Lin L, Xie T, Peng L, Xu J, Yang R, Ji J, Zhao X. High-resolution lipidomics reveals dysregulation of lipid metabolism in respiratory syncytial virus pneumonia mice[J/OL]. RSC Adv,2018, 8(51):29368-29377. DOI:10.1039/c8ra05640d.

[3] Mazzon M, Mercer J. Lipid interactions during virus entry and infection[J/OL]. Cell Microbiol, 2014, 16(10):1493-1502. DOI:10.1111/cmi.12340.

[4] San-Juan-Vergara H, Sampayo-Escobar V, Reyes N,Cha B, Pacheco-Lugo L, Wong T, Peeples M E,Collins P L, Castano M E, Mohapatra S S. Cholesterolrich microdomains as docking platforms for respiratory syncytial virus in normal human bronchial epithelial cells[J/OL]. J Virol, 2012, 86(3):1832-1843. DOI:10.1128/JVI.06274-11.

[5] Brown G, Jeffree C E, McDonald T, Rixon H W,Aitken J D, Sugrue R J. Analysis of the interaction between respiratory syncytial virus and lipid-rafts in Hep2 cells during infection[J/OL]. Virology. 2004;327(2):175-185. DOI:10.1016/j.virol.2004.06.038.

[6] Veit M. Palmitoylation of virus proteins[J/OL]. Biol Cell, 2012, 104(9):493-515. DOI:10.1111/boc.201200006.

[7] Resh M D. Fatty acylation of proteins:new insights into membrane targeting of myristoylated and palmitoylated proteins[J/OL]. Biochim Biophys Acta. 1999;1451(1):1-16. DOI:10.1016/s0167-4889(99)00075-0.

[8] Yeo D S, Chan R, Brown G, Ying L, Sutejo R,Aitken J, Tan B H, Wenk M R, Sugrue R J. Evidence that selective changes in the lipid composition of raftmembranes occur during respiratory syncytial virus infection[J/OL]. Virology, 2009, 386(1):168-182.DOI:10.1016/j.virol.2008.12.017.

[9] Numata M, Kandasamy P, Nagashima Y, Fickes R,Murphy R C, Voelker D R. Phosphatidylinositol inhibits respiratory syncytial virus infection[J/OL]. J Lipid Res,2015, 56(3):578-587. DOI:10.1194/jlr.M055723.

[10]Toker A, Cantley L C. Signalling through the lipid products of phosphoinositide-3-OH kinase[J/OL].Nature. 1997;387(6634):673-676. DOI:10.1038/42648.

[11]Chen L F, Xu W B, Li Y Y, Chen N H, Luo D, Song Q Y, Tang W, Huang Z G, Li Y L, Liu Z, Li M M.Inhibitory Effect of PIK-24 on Respiratory Syncytial Virus Entry by Blocking Phosphatidylinositol-3 Kinase Signaling[J/OL]. Antimicrob Agents Chemother,2020, 64(10). DOI:10.1128/AAC.00608-20.

[12]Ludwig A, Nguyen T H, Leong D, Ravi L I, Tan B H, Sandin S, Sugrue R J. Caveolae provide a specialized membrane environment for respiratory syncytial virus assembly[J/OL]. J Cell Sci. 2017;130(6):1037-1050. DOI:10.1242/jcs.198853.

[13]Ravi L I, Tan T J, Tan B H, Sugrue R J. Virusinduced activation of the rac1 protein at the site of respiratory syncytial virus assembly is a requirement for virus particle assembly on infected cells[J/OL].Virology, 2021, 557:86-99. DOI:10.1016/j.virol.2021.02.008.

[14]Bajimaya S, Frankl T, Hayashi T, Takimoto T.Cholesterol is required for stability and infectivity of influenza A and respiratory syncytial viruses[J/OL].Virology, 2017, 510:234-241. DOI:10.1016/j.virol.2017.07.024.

[15]Chang T H, Segovia J, Sabbah A, Mgbemena V, Bose S. Cholesterol-rich lipid rafts are required for release of infectious human respiratory syncytial virus particles[J/OL]. Virology, 2012, 422(2):205-213. DOI:10.1016/j.virol.2011.10.029.

[16]Kleinehr J, Wilden J J, Boergeling Y, Ludwig S,Hrincius E R. Metabolic Modifications by Common Respiratory Viruses and Their Potential as New Antiviral Targets[J/OL]. Viruses, 2021, 13(10).DOI:10.3390/v13102068.

[17]Martin-Vicente M, Gonzalez-Riano C, Barbas C,Jimenez-Sousa M A, Brochado-Kith O, Resino S,Martinez I. Metabolic changes during respiratory syncytial virus infection of epithelial cells[J/OL].PLoSOne, 2020, 15(3):e0230844. DOI:10.1371/journal.pone.0230844.

[18]Morris D R, Qu Y, Agrawal A, Garofalo R P, Casola A. HIF-1alpha Modulates Core Metabolism and Virus Replication in Primary Airway Epithelial Cells Infected with Respiratory Syncytial Virus[J/OL]. Viruses,2020, 12(10). DOI:10.3390/v12101088.

[19]Ohol Y M, Wang Z, Kemble G, Duke G. Direct Inhibition of Cellular Fatty Acid Synthase Impairs Replication of Respiratory Syncytial Virus and Other Respiratory Viruses[J/OL]. PLoS One, 2015, 10(12):e0144648. DOI:10.1371/journal.pone.0144648.

[20]Hosakote Y M, Komaravelli N, Mautemps N, Liu T,Garofalo R P, Casola A. Antioxidant mimetics modulate oxidative stress and cellular signaling in airway epithelial cells infected with respiratory syncytial virus[J/OL].Am J Physiol Lung Cell Mol Physiol, 2012, 303(11):L991-1000. DOI:10.1152/ajplung.00192.2012.

[21]Walsh P, Behrens N, Carvallo Chaigneau F R,McEligot H, Agrawal K, Newman J W, Anderson M,Gershwin L J. A Randomized Placebo Controlled Trial of Ibuprofen for Respiratory Syncytial Virus Infection in a Bovine Model[J/OL]. PLoS One, 2016, 11(4):e0152913. DOI:10.1371/journal.pone.0152913.

[22]Liu T, Zaman W, Kaphalia B S, Ansari G A, Garofalo R P, Casola A. RSV-induced prostaglandin E2production occurs via cPLA2 activation:role in viral replication[J/OL]. Virology, 2005, 343(1):12-24.DOI:10.1016/j.virol.2005.08.012.

[23]Snider A J, Orr Gandy K A, Obeid L M. Sphingosine kinase:Role in regulation of bioactive sphingolipid mediators in inflammation[J/OL]. Biochimie, 2010, 92(6):707-715. DOI:10.1016/j.biochi.2010.02.008.

[24]Gonzalez-Garcia L D, Martinez-Castillo M, VargasPavia T A, Ulloa-Aguilar J M, Arevalo-Romero H,Leon-Reyes G, Helguera-Repetto A C, Garcia-Cordero J, Leon-Juarez M. Inhibition of AMP-activated protein kinase in respiratory syncytial virus infection activates lipid metabolism[J/OL]. Arch Virol, 2021, 166(4):1177-1182. DOI:10.1007/s00705-021-04974-7.

[25]Lin L, An L, Chen H, Feng L, Lu M, Liu Y, Chu C,Shan J, Xie T, Wang X, Wang S. Integrated Network Pharmacology and Lipidomics to Reveal the Inhibitory Effect of Qingfei Oral Liquid on Excessive Autophagy in RSV-Induced Lung Inflammation[J/OL]. Front Pharmacol, 2021, 12:777689. DOI:10.3389/fphar.2021.777689.

[26]Dai P, Tang Z, Qi M, Liu D, Bajinka O, Tan Y.Dispersion and utilization of lipid droplets mediates respiratory syncytial virus-induced airway hyperresponsiveness[J/OL]. Pediatr Allergy Immunol,2022, 33(1):e13651. DOI:10.1111/pai.13651.

[27]Numata M, Nagashima Y, Moore M L, Berry K Z,Chan M, Kandasamy P, Peebles R S, Jr., Murphy R C, Voelker D R. Phosphatidylglycerol provides shortterm prophylaxis against respiratory syncytial virus infection[J/OL]. J Lipid Res, 2013, 54(8):2133-2143. DOI:10.1194/jlr.M037077.

[28]Tibboel J, Reiss I, de Jongste J C, Post M.Sphingolipids in lung growth and repair[J/OL]. Chest,2014, 145(1):120-128. DOI:10.1378/chest.13-0967.

[29]Worgall T S, Veerappan A, Sung B, Kim B I, Weiner E, Bholah R, Silver R B, Jiang X C, Worgall S.Impaired sphingolipid synthesis in the respiratory tract induces airway hyperreactivity[J/OL]. Sci Transl Med,2013, 5(186):186ra167. DOI:10.1126/scitranslmed.3005765.

[30]Barreira E R, Precioso A R, Bousso A. Pulmonary surfactant in respiratory syncytial virus bronchiolitis:the role in pathogenesis and clinical implications[J/OL].Pediatr Pulmonol, 2011, 46(5):415-420. DOI:10.1002/ppul.21395.

[31]Churiso G, Husen G, Bulbula D, Abebe L. Immunity Cell Responses to RSV and the Role of Antiviral Inhibitors:A Systematic Review[J/OL]. Infect Drug Resist, 2022, 15:7413-7430. DOI:10.2147/IDR.S387479.

[32]Zhu L, Zhao Q, Yang T, Ding W, Zhao Y. Cellular metabolism and macrophage functional polarization[J/OL]. Int Rev Immunol, 2015, 34(1):82-100. DOI:10.3109/08830185.2014.969421.

[33]Odegaard J I, Chawla A. Alternative macrophage activation and metabolism[J/OL]. Annu Rev Pathol,2011, 6:275-297. DOI:10.1146/annurev-pathol-011110-130138.

[34]Triggiani M, Oriente A, de Crescenzo G, Rossi G,Marone G. Biochemical functions of a pool of arachidonic acid associated with triglycerides in human inflammatory cells[J/OL]. Int Arch Allergy Immunol.1995;107(1-3):261-263. DOI:10.1159/000236997.

[35]Chouinard F, Turcotte C, Guan X, Larose M C,Poirier S, Bouchard L, Provost V, Flamand L,Grandvaux N, Flamand N. 2-Arachidonoyl-glyceroland arachidonic acid-stimulated neutrophils release antimicrobial effectors against E. coli, S. aureus, HSV-1, and RSV[J/OL]. J Leukoc Biol, 2013, 93(2):267-276. DOI:10.1189/jlb.0412200.

[36]Ji J J, Sun Q M, Nie D Y, Wang Q, Zhang H, Qin F F, Wang Q S, Lu S F, Pang G M, Lu Z G. Probiotics protect against RSV infection by modulating the microbiota-alveolar-macrophage axis[J/OL]. Acta Pharmacol Sin, 2021, 42(10):1630-1641. DOI:10.1038/s41401-020-00573-5.

[37]Antunes K H, Fachi J L, de Paula R, da Silva E F,Pral L P, Dos Santos A A, Dias G B M, Vargas J E,Puga R, Mayer F Q, Maito F, Zarate-Blades C R,Ajami N J, Sant'Ana M R, Candreva T, Rodrigues H G, Schmiele M, Silva Clerici M T P, Proenca-Modena J L, Vieira A T, Mackay C R, Mansur D, Caballero M T, Marzec J, Li J, Wang X, Bell D, Polack F P,Kleeberger S R, Stein R T, Vinolo M A R, de Souza A P D. Microbiota-derived acetate protects against respiratory syncytial virus infection through a GPR43-type 1 interferon response[J/OL]. Nat Commun, 2019,10(1):3273. DOI:10.1038/s41467-019-11152-6.

[38]Park J W, Kim H Y, Kim M G, Jeong S, Yun C H,Han S H. Short-chain Fatty Acids Inhibit Staphylococcal Lipoprotein-induced Nitric Oxide Production in Murine Macrophages[J/OL]. Immune Netw, 2019, 19(2):e9.DOI:10.4110/in.2019.19.e9.

[39]Antunes K H, Stein R T, Franceschina C, da Silva E F, de Freitas D N, Silveira J, Mocellin M, Leitao L,Fachi J L, Pral L P, Gonzalez A, Oliveira S, Duarte L, Cassao G, Goncalves J I B, Reis T M, Abbadi B L,Dornelles M, Sperotto N D M, Rigo M, Rodrigues H,Jones M, Epifanio M, Guima S, Setubal J C, Jorge T R, Mansur D S, Mayer F Q, Varela A P M, Bizarro C V, Machado P, Basso L A, Polack F P, Custovic A,Vinolo M A R, de Souza A P D. Short-chain fatty acid acetate triggers antiviral response mediated by RIG-I in cells from infants with respiratory syncytial virus bronchiolitis[J/OL]. EBioMedicine, 2022, 77:103891.DOI:10.1016/j.ebiom.2022.103891.

[40]Ling Z, Tran K C, Teng M N. Human respiratory syncytial virus nonstructural protein NS2 antagonizes the activation of beta interferon transcription by interacting with RIG-I[J/OL]. J Virol, 2009, 83(8):3734-3742.DOI:10.1128/JVI.02434-08.

[41]Du L N, Xie T, Xu J Y, Kang A, Di L Q, Shan J J,Wang S C. A metabolomics approach to studying the effects of Jinxin oral liquid on RSV-infected mice using UPLC/LTQ-Orbitrap mass spectrometry[J/OL]. J Ethnopharmacol, 2015, 174:25-36. DOI:10.1016/j.jep.2015.07.040.

[42]An L, Lu M, Xu W, Chen H, Feng L, Xie T, Shan J,Wang S, Lin L. Qingfei oral liquid alleviates RSVinduced lung inflammation by promoting fatty-aciddependent M1/M2 macrophage polarization via the Akt signaling pathway[J/OL]. J Ethnopharmacol, 2022,298:115637. DOI:10.1016/j.jep.2022.115637.

[43]Teoh S T, Leimanis-Laurens M L, Comstock S S,Winters J W, Vandenbosch N L, Prokop J W,Bachmann A S, Lunt S Y, Rajasekaran S. Combined plasma and urinary metabolomics uncover metabolic perturbations associated with severe respiratory syncytial viral infection and future development of asthma in infant patients[J/OL]. Metabolites, 2022, 12(2). DOI:10.3390/metabo12020178.

[44]Schoggins J W, Randall G. Lipids in innate antiviral defense[J/OL]. Cell Host Microbe, 2013, 14(4):379-385. DOI:10.1016/j.chom.2013.09.010.

[45]Gorabi A M, Kiaie N, Bianconi V, Jamialahmadi T,Al-Rasadi K, Johnston T P, Pirro M, Sahebkar A.Antiviral effects of statins[J/OL]. Prog Lipid Res,2020, 79:101054. DOI:10.1016/j.plipres.2020.101054.

[46]Kamphuis T, Meijerhof T, Stegmann T, Lederhofer J,Wilschut J, de Haan A. Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice[J/OL]. PLoS One, 2012, 7(5):e36812. DOI:10.1371/journal.pone.0036812.

[47]Park S, Lee Y, Kwon Y M, Lee Y T, Kim K H, Ko E J, Jung J H, Song M, Graham B, Prausnitz M R,Kang S M. Vaccination by microneedle patch with inactivated respiratory syncytial virus and monophosphoryl lipid A enhances the protective efficacy and diminishes inflammatory disease after challenge[J/OL]. PLoS One, 2018, 13(10):e0205071. DOI:10.1371/journal.pone.0205071.

[48]Gabor K A, Fessler M B. Roles of the Mevalonate Pathway and Cholesterol Trafficking in Pulmonary Host Defense[J/OL]. Curr Mol Pharmacol. 2017;10(1):27-45. DOI:10.2174/1874467209666160112123603.

[49]Fessler M B. Regulation of Adaptive Immunity in Health and Disease by Cholesterol Metabolism[J/OL].Curr Allergy Asthma Rep, 2015, 15(8):48. DOI:10.1007/s11882-015-0548-7.

[50]Fessler M B, Summer R S. Surfactant Lipids at the Host–Environment Interface. SensorsMetabolic,Suppressors, and Effectors of Inflammatory Lung Disease[J/OL]. American Journal of Respiratory Cell and Molecular Biology, 2016, 54(5):624-635. DOI:10.1165/rcmb.2016-0011PS.

[51]Fessler M B. A New Frontier in Immunometabolism.Cholesterol in Lung Health and Disease[J/OL]. Ann Am Thorac Soc, 2017, 14(Supplement_5):S399-S405. DOI:10.1513/AnnalsATS.201702-136AW.